Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/59466
Type: Artigo de Periódico
Title: Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
Authors: Gustavo Fernandes
Daniel Girardi
João Paulo Bernardes
Felipe Paiva Fonseca
Eduardo Fregnani
Abstract: Background: Ameloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Systemic therapy is not established in the literature. Case presentation: We present a case of a 29-year-old woman diagnosed with an ameloblastoma of the left mandible who had been subjected to several surgical procedures over twenty years due to multiple local recurrences. Molecular testing revealed a BRAF V600E mutation, and vemurafenib was started. She experienced complete resolution of symptoms related to the disease, and image scans evidenced continuous shrinkage of the neoplastic lesion after eleven months of therapy. Conclusion: This is the first report showing clinical benefit and radiological response with vemrafenib for recurrent ameloblastoma. Targeted therapy addressing BRAF V600E mutation has the potential to change clinical practice of this rare disease.
Subject: Ameloblastoma
Neoplasms
Mandible
language: eng
metadata.dc.publisher.country: Brasil
Publisher: Universidade Federal de Minas Gerais
Publisher Initials: UFMG
metadata.dc.publisher.department: FAO - DEPARTAMENTO DE CLÍNICA
Rights: Acesso Aberto
metadata.dc.identifier.doi: https://doi.org/10.1186%2Fs12885-018-4802-y
URI: http://hdl.handle.net/1843/59466
Issue Date: 12-Sep-2018
metadata.dc.url.externa: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134697/
metadata.dc.relation.ispartof: BMC Cancer
Appears in Collections:Artigo de Periódico



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.